Holen Sie sich die Stockscreener-App
8.16
13.56%
-1.28
Handel nachbörslich:
8.32
0.16
+1.96%
Schlusskurs vom Vortag:
$9.44
Offen:
$9.15
24-Stunden-Volumen:
61,911
Relative Volume:
0.91
Marktkapitalisierung:
$40.72M
Einnahmen:
$34.77M
Nettoeinkommen (Verlust:
$-74.04M
KGV:
-1.018
EPS:
-8.0157
Netto-Cashflow:
$-79.76M
1W Leistung:
-20.23%
1M Leistung:
-1.45%
6M Leistung:
-17.93%
1J Leistung:
-82.26%
1-Tages-Spanne:
$8.00
$9.15
1-Wochen-Bereich:
$8.00
$10.03
52-Wochen-Spanne:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
8.16 | 47.11M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Using data filters to optimize entry into Mersana Therapeutics Inc.July 2025 PostEarnings & Detailed Earnings Play Strategies - newser.com
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarterBull Run & Reliable Volume Spike Trade Alerts - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationWeekly Trade Analysis & Risk Controlled Swing Alerts - newser.com
Will Mersana Therapeutics Inc. stock benefit from infrastructure spendingEarnings Overview Summary & Stock Portfolio Risk Management - newser.com
How Mersana Therapeutics Inc. stock benefits from global expansionJuly 2025 Volume & Stepwise Swing Trade Plans - newser.com
How cyclical is Mersana Therapeutics Inc. (0M4) stock compared to rivalsMarket Sentiment Report & Daily Momentum Trading Reports - newser.com
How Mersana Therapeutics Inc. (0M4) stock reacts to weak economyShort Setup & Safe Entry Momentum Stock Tips - newser.com
Heatmap analysis for Mersana Therapeutics Inc. and competitorsEarnings Trend Report & Low Risk Entry Point Tips - newser.com
News impact scoring models applied to Mersana Therapeutics Inc.Earnings Summary Report & Verified High Yield Trade Plans - newser.com
Can you recover from losses in Mersana Therapeutics Inc.Weekly Stock Recap & Long-Term Growth Plans - newser.com
Is Mersana Therapeutics Inc. stock ready for a breakoutJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumMarket Activity Recap & Daily Stock Trend Watchlist - newser.com
Price action breakdown for Mersana Therapeutics Inc.2025 Key Highlights & Community Verified Swing Trade Signals - newser.com
How Mersana Therapeutics Inc. (0M4) stock responds to job market shiftsRecession Risk & Weekly Chart Analysis and Guides - newser.com
Why Mersana Therapeutics Inc. stock could rally in 2025Earnings Miss & Community Supported Trade Ideas - newser.com
Detecting price anomalies in Mersana Therapeutics Inc. with AIJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
Earnings visualization tools for Mersana Therapeutics Inc.Market Trend Report & Capital Protection Trade Alerts - newser.com
What momentum shifts mean for Mersana Therapeutics Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Does Mersana Therapeutics Inc. qualify in momentum factor screeningShare Buyback & Free Reliable Trade Execution Plans - newser.com
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):